Literature DB >> 30207283

Radiologic and autopsy findings in a case of fatal immune checkpoint inhibitor-associated pneumonitis.

Meghan Shea1, Deepa Rangachari1, Robert W Hallowell1, Norris I Hollie2, Daniel B Costa1, Paul A VanderLaan3.   

Abstract

Oncologists are increasingly managing drug-induced pneumonitis in lung cancer patients treated with PD-1/PD-L1 immune checkpoint inhibitors. To date only few studies on the topic have described both radiologic and pathologic findings in these patients. Here, we report a fatal case of immune checkpoint inhibitor-associated pneumonitis initially presenting with an organizing pneumonia, but who rapidly developed acute respiratory distress syndrome (confirmed histologically at the time of autopsy). As such, this case illustrates the need for clinicians to maintain a high index of suspicion for immune checkpoint inhibitor associated pneumonitis and have a low threshold to perform CT imaging in any symptomatic patient receiving checkpoint inhibition therapy. CLINICAL PRACTICE POINTS.
Copyright © 2018 Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Autopsy; Lung cancer; PD-L1; Pembrolizumab; Pneumonitis

Mesh:

Substances:

Year:  2018        PMID: 30207283     DOI: 10.1016/j.ctarc.2018.02.004

Source DB:  PubMed          Journal:  Cancer Treat Res Commun        ISSN: 2468-2942


  2 in total

1.  Knowledge Gaps and Research Priorities in Immune Checkpoint Inhibitor-related Pneumonitis. An Official American Thoracic Society Research Statement.

Authors:  Catherine R Sears; Tobias Peikert; Jennifer D Possick; Jarushka Naidoo; Mizuki Nishino; Sandip P Patel; Philippe Camus; Mina Gaga; Edward B Garon; Michael K Gould; Andrew H Limper; Philippe R Montgrain; William D Travis; M Patricia Rivera
Journal:  Am J Respir Crit Care Med       Date:  2019-09-15       Impact factor: 21.405

Review 2.  The knowns & unknowns of pulmonary toxicity following immune checkpoint inhibitor therapies: a narrative review.

Authors:  Alistair R Miller; Renee Manser
Journal:  Transl Lung Cancer Res       Date:  2021-06
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.